Transcroporal Artificial Urinary Sphincter Placement With Closure of Corporal Bodies-A Long-Term Analysis of Functional Outcomes.
AMS 800
artificial urinary sphincter
corporal closure
reconstructive urology
stress urinary
transcorporal cuffs
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
04
2022
accepted:
09
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
An artificial urinary sphincter (AUS) is the gold standard for postoperative stress urinary incontinence (SUI). The transcorporal AUS (TC) placement constitutes the main salvage option in high-risk patients suffering from SUI with fragile urethras. The literature analyzing long-term outcomes with respect to explantation rates, continence, and erectile function is scarce. Retrospective data collection was performed in 2011. TC was applied according to a standardized protocol. TC was implanted after bulbar urethroplasty or double-cuff (DC) explantation. After TC placement, the tunica albuginea was closed in order to minimize the risk of postoperative bleedings and erectile dysfunction. Activation was performed 6 weeks postoperatively. Further follow-up (FU) was scheduled 6/24 months postoperatively and every 2 years thereafter. Primary/secondary endpoints were explantation/objective, subjective, and social continence rates. Objective or social continence was defined as the use of 0 pads/day or <2 pads/day, respectively. Thereupon, postoperative bleedings and erectile function were analyzed. A total of 39 high-risk patients were available for analysis. The median age was 72 years. In total, 84.6%, 10.3%, and 2.6% had a history of radical prostatectomy, TURP, and radical cystectomy, respectively. In total, 61.5% had a history of radiation therapy of the prostate, 41% had a history of urethral surgery, and 95% had a history of double cuff explantation. The median FU was 27 months. Objective, subjective, and social continence were 54.5%, 69.7%, and 78.8%, respectively. The median pad usage was 1 pad/day [1-2.5]. Only one patient suffered from a postoperative hematoma. In total, 15.4% of the patients were able to have an erection preoperatively, compared to 7.7% after TC placement. The estimated mean explantation-free survival of the TC was 83 months in the Kaplan-Meier analysis. TC AUS implantation constitutes a viable salvage approach in high-risk SUI patients with a mean device survival of almost 7 years and high social continence rates of almost 80%. An intraoperative closure of the tunica albuginea after TC placement allows for very low rates of postoperative hematoma and supports postoperative erectile rigidity.
Identifiants
pubmed: 35722536
doi: 10.3389/fsurg.2022.918011
pmc: PMC9198723
doi:
Types de publication
Journal Article
Langues
eng
Pagination
918011Informations de copyright
Copyright © 2022 Maurer, Dahlem, Howaldt, Riechardt, Fisch, Ludwig and Engel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BJU Int. 2013 Dec;112(8):1163-8
pubmed: 24053170
World J Urol. 2020 Sep;38(9):2289-2294
pubmed: 31797074
BJOG. 2004 Aug;111(8):859-62
pubmed: 15270937
J Urol. 2015 Dec;194(6):1692-6
pubmed: 26141851
J Urol. 2007 Mar;177(3):1015-9; discussion 1019-20
pubmed: 17296400
Can Urol Assoc J. 2008 Oct;2(5):536-9
pubmed: 18953453
Int J Urol. 2012 Sep;19(9):861-6
pubmed: 22571275
Eur Urol. 2011 Mar;59(3):387-400
pubmed: 21130559
BJU Int. 2019 Dec;124(6):1040-1046
pubmed: 31351030
J Urol. 2004 Feb;171(2 Pt 1):703-7; discussion 707-8
pubmed: 14713791
Adv Urol. 2012;2012:287489
pubmed: 22649446
World J Urol. 2021 Dec;39(12):4449-4457
pubmed: 34272596
Urology. 2019 Nov;133:234-239
pubmed: 31352019
Eur Urol. 2009 May;55(5):1037-63
pubmed: 19185977
BJU Int. 2016 Oct;118(4):625-32
pubmed: 26917355
J Urol. 2007 Mar;177(3):1021-5
pubmed: 17296403
Urology. 2012 Apr;79(4):922-8
pubmed: 22305763
J Urol. 2002 May;167(5):2075-8; discussion 2079
pubmed: 11956443
Can J Urol. 2013 Jun;20(3):6773-7
pubmed: 23783046
Transl Androl Urol. 2017 Aug;6(4):682-694
pubmed: 28904901